Last reviewed · How we verify
Perampanel 2 week titration
Perampanel, marketed by Kimford Jay Meador, is a drug with a key composition patent expiring in 2028. Its primary strength lies in its established market presence and ongoing revenue generation. The primary risk is the potential increase in competition post-patent expiry in 2028.
At a glance
| Generic name | Perampanel 2 week titration |
|---|---|
| Also known as | Fycompa |
| Sponsor | Kimford Jay Meador |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Perampanel Titration and Cognitive Effects (PHASE4)
- Fycompa Titration Intervals and Effects on Retention Rate (PHASE4)
- Study to Evaluate the Efficacy and Safety of Perampanel as Monotherapy or First Adjunctive Therapy in Subjects With Partial Onset Seizures With or Without Secondarily Generalized Seizures or With Primary Generalized Tonic-Clonic Seizures (PHASE4)
- A Multi-center RWS of Perampanel as an add-on Treatment for Epileptic Seizures in Chinese Children
- Study for Verification of Efficacy and Safety for Perampanel Monotherapy in Untreated Participants With Partial Onset Seizures (Including Secondarily Generalized Seizures (FREEDOM Study) (PHASE3)
- Trial Evaluating the Efficacy and Safety of Perampanel Added to Monotherapy in Participants With Partial Onset Seizures With or Without Secondary Generalization (PHASE4)
- A Long-term Extension Study of E2007 in Patients With Refractory Partial Seizures Uncontrolled With Other Anti-Epileptic Drugs (AEDs) (PHASE2)
- Perampanel for Treatment of Adults With Refractory Focal Epilepsy : a Pilot Study. (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Perampanel 2 week titration CI brief — competitive landscape report
- Perampanel 2 week titration updates RSS · CI watch RSS
- Kimford Jay Meador portfolio CI